-transparent.png){kind=logo}
Administration of a mixture containing Lactobacillus casei YIT 9018 (LC9018) and methylcholanthrene-induced fibrosarcoma (Meth A) cells into the peritoneum of syngeneic BALB/c mice suppressed the tumour growth and protected the mice from tumour death. With the appearance of the anti-tumour activity, serum complement-dependent tumour cytotoxic (CDC) antibody was induced on the 5th day after the administration as a result of the adjuvant effect. The cytotoxic antibody was not found in serum on the 5th day after inoculation of Meth A cells alone, but it was induced before the mice died of the tumours. Adjuvant induction of the cytotoxic serum antibody at an early time was also observed using Kirsten murine sarcoma virus-transformed tumour (K234) cells. Both of these cytotoxic antibodies in sera from Meth A-suppressed and the tumour-bearing mice were specific for the tumour cells and were IgM class, since they were absorbed with rabbit anti-mouse IgM antibody. However, the cytotoxic antibody was not found in the peritoneal cavity which was the tumour inoculation site, but binding antibody against the tumour cells was faintly detected in the region using an enzyme-linked immunoabsorbent assay (ELISA). In neutralization tests, the cytotoxic antibody did not exert anti-tumour activity in recipient mice when it was administered to the mice along with the tumour cells or when it was administered i.v. at the time of tumour inoculation. Moreover, the cytotoxic antibody was not available for the antibody-dependent cell-mediated cytotoxicity (ADCC). These results suggest that the cytotoxic antibody did not exert anti-tumour activity in the tumour-suppressed mice. In contrast, peritoneal exudate cells (PEC) on the 5th day, and PEC and spleen cells on the 15th day after i.p. administration of the mixture exerted strong anti-tumour activity as measured by the Winn test. In conclusion, the adjuvant effect of LC9018 induced tumour-specific humoral and cellular immunities but the anti-tumour activity was dependent only on the cellular effectors of the host. The possible use of LC9018 in tumour immunotherapy is discussed.
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
December 1996,
Journal of pharmaceutical sciences,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
June 1983,
Hiroshima journal of medical sciences,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
January 1983,
Microbiology and immunology,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
January 1989,
Biotherapy (Dordrecht, Netherlands),
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
February 1982,
Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
January 1988,
Cancer immunology, immunotherapy : CII,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
January 2000,
Zhurnal mikrobiologii, epidemiologii i immunobiologii,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
January 1985,
Cancer immunology, immunotherapy : CII,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
September 1994,
Zhongguo yao li xue bao = Acta pharmacologica Sinica,
N Yasutake, and
M Ohwaki, and
M Mutai, and
Y Koide, and
T Yoshida
January 1988,
Biotherapy (Dordrecht, Netherlands),
